Results 31 to 40 of about 9,946,516 (158)

PF398 KNOCKDOWN OF LASP1 IN CXCR4 EXPRESSING CML CELLS PROMOTES CELL PERSISTENCE, PROLIFERATION AND TKI RESISTANCE

HemaSphere, Volume 3, Issue S1, Page 151, June 2019., 2019
Background: Chronic myeloid leukemia (CML) is a hematopoietic stem cell disorder characterized by a fusion protein, the constitutively active BCR–ABL tyrosine kinase, leading to expansion of differentiated granulocytes. Although tyrosine kinase inhibitors (TKI) have significantly improved patient care, minimal residual disease (MRD) remains a clinical ...
A.B. Herrmann, M.‐L. Müller, M.F. Orth, J.P. Müller, A. Zernecke, A. Hochhaus, T. Ernst, E. Butt, J.J. Frietsch   +8 more
wiley   +1 more source

PF399 GENE EXPRESSION PROFILING OF CD26+ LEUKEMIC STEM CELL POPULATION FROM CML PATIENTS

HemaSphere, Volume 3, Issue S1, Page 151-152, June 2019., 2019
Background: Nowadays, chronic myeloid leukemia (CML) has become a well manageable disease and majority of the patients achieve remission on tyrosine kinase inhibitor (TKI) treatment. However, the disease usually shows a low‐level persistence during therapy that arises from putative leukemic stem cells (LSC), which are, despite BCR‐ABL1 positivity ...
D. Smitalová, M. Culen, Z. Herudkova, E. Budinska, J. Mayer, Z. Racil, M. Romzova   +6 more
wiley   +1 more source

PF401 IMMUNE SYSTEM AND CHRONIC MYELOID LEUKEMIA: THE IMPACT OF TYROSINE KINASE INHIBITORS

HemaSphere, Volume 3, Issue S1, Page 152-153, June 2019., 2019
Background: During carcinogenesis, tumor cells alter their immunogenicity in an attempt to escape surveillance of the immune system (SI). This surveillance process involves NK cells and T lymphocytes, and various immunological factors, in order to combat tumor progression.
R.S. Alves, S.E. McArdle, J. Vadakekolathu, A.C. Gonçalves, P. Freitas‐Tavares, A. Pereira, A.M. Almeida, A.B. Sarmento‐Ribeiro, S. Rutella   +8 more
wiley   +1 more source

PF402 PECULIARITIES OF THE EXPRESSION OF KI‐67 AND CD34 HEMOPOIETIC PRECURSOR CELLS IN PB AND BM OF CML PATIENTS WITH THE DIFFERENT RESPONSES TO IMATINIB AND NILOTINIB THERAPY

HemaSphere, Volume 3, Issue S1, Page 153, June 2019., 2019
Background: The main feature of CML is the formation of the BCR‐ABL gene, the product of which has a pronounced tyrosine kinase activity, which is due to the suppressing effect of the protein regulators of proliferation and apoptosis. The result is an increase of the proliferation of tumor cells, the marker of which is the Ki‐67 protein.
T. Perekhrestenko, I. Sviezhentseva, U. Melnyk, I. Dyagil   +3 more
wiley   +1 more source

Workflow for cell-based BcrAbl kinase activity assay.

, 2016
Non-adherent K562 cells are seeded into a 1 mL per well capacity, 96-well filter plate, treated with a BcrAbl kinase inhibitor, and incubated with the cell-penetrating BcrAbl substrate peptide.
Steven B. Ouellette (1649494), Laurie L. Parker (379405), Brett M. Noel (3106581)   +2 more
core   +1 more source

Pregnancy with chronic myeloid leukemia: case report and literature review

, 2019
Chronic myeloid leukemia (CML) is a myelo proliferative disorder with clonal expansion of transformed primitive hematopoietic progenitor cells. This genetic anomaly arises from an exchange of genetic material between chromosome 9 and 22, which results in
T. S. Chowdhury, Israt Jereen, T. Chowdhury   +2 more
semanticscholar   +1 more source

PF403 NEGATIVE MR4.0 CHRONIC MYELOID LEUKEMIA AND ITS IMPLICATIONS FOR TREATMENT‐FREE REMISSION

HemaSphere, Volume 3, Issue S1, Page 153-154, June 2019., 2019
Background: In the last few years, several clinical discontinuation trials have demonstrated that 40–60% of chronic phase CML patients (CP‐CML) who have achieved a stable deep molecular response, can stop therapy without relapsing. However, there is no consensus as to whether or not the depth of the molecular response is a prognostic factor for ...
N. Cerveira, J. Diamond, S. Matos, M.L. Amorim, M. Coucelo, S. Bizarro, A.T. Simões, F. Pierdomenico, M. Lopes, L. Ribeiro, M. Carmo‐Fonseca, J.E. Guimarães, A. Almeida, M.R. Teixeira   +13 more
wiley   +1 more source

PF-114, a Novel Inhibitor of Bcr-Abl Chimeric Tyrosine Kinase, Attenuates Intracellular CrkL Phosphorylation and Kills Chronic Myeloid Leukemia Cells

, 2016
Background & Aims. The chimeric tyrosine kinase BcrAbl triggers malignant transformation of myeloid cells via phosphorylation of a number of substrates including the CrkL adaptor protein.
E.A. Kolotova, V. Tatarskiĭ, Alexey A. Zeifman, O. Stroganov, VS Stroilov, I. Titov, F. Novikov, A. Kalinina, G. Chilov, A. Shtil'   +9 more
semanticscholar   +1 more source

S881 PREGNANCY OUTCOME IN FEMALE PATIENTS WITH CHRONIC MYELOID LEUKEMIA WORLDWIDE: ANALYSIS OF 305 CASES OF THE EUROPEAN LEUKEMIA NET REGISTRY

HemaSphere, Volume 3, Issue S1, Page 395-396, June 2019., 2019
Background: Family planning is important in patients (pts) with chronic myeloid leukemia (CML) who can have a near normal lifespan in tyrosine kinase inhibitors (TKI) era. Management of CML on conceptions and pregnancies is not defined as cases are rare and data are scarce.
E. Chelysheva, A. Turkina, D. Rea, P. Rousselot, F.E. Nicolini, M.M. Trawinska, A. Romano, M. Malagola, D. Cangemi, I. Dyagil, K. Kotlyarchuk, K. Kazakbaeva, S. Saliev, C. Pavlovsky, B. Moiraghi, D.‐W. Kim, H. Klamova, M. Yassin, K. Meliktesyan, G. Mikhailov, P. Ganeva, S. Osorio, M. Mauro, E. Polushkina, R. Shmakov, J. Chabaeva, S. Kulikov, E. Abruzzese   +27 more
wiley   +1 more source

Peroxisomal membrane proteins insert into the endoplasmic reticulum [PDF]

, 2010
We show that a comprehensive set of 16 peroxisomal membrane proteins (PMPs) encompassing all types of membrane topologies first target to the endoplasmic reticulum (ER) in Saccharomyces cerevisiae.
Sub Cellular Protein Chemistry, van der Zand, A., Tabak, H.F., Braakman, L.J., Cellular Protein Chemistry   +4 more
core   +1 more source